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Abstract
The concept of replenishing or elevating NAD+ availability to combat metabolic 
disease and ageing is an area of intense research. This has led to a need to define the 
endogenous regulatory pathways and mechanisms cells and tissues utilise to maximise 
NAD+ availability such that strategies to intervene in the clinical setting are able to 
be fully realised. This review discusses the importance of different salvage pathways 
involved in metabolising the vitamin B3 class of NAD+ precursor molecules, with a 
particular focus on the recently identified nicotinamide riboside kinase pathway at both 
a tissue-specific and systemic level.
NAD+ as a redox cofactor and 
signalling molecule
The vital role of NAD+ in redox metabolism was first 
described in 1906 by Arthur Harden as being a required 
cofactor for alcohol fermentation (Harden & Young 
1906). It has since been well established as a redox 
coenzyme necessary for many redox reactions (Euler-
Chelpin 1966). During these redox events NAD+ can be 
reduced by accepting electrons from donor molecules or, 
in reverse, NADH can be oxidised to NAD+ by donating 
electrons. This interchange of electrons allows catalysis 
of reversible transhydrogenase reactions (Warburg & 
Christian 1936). Notably, NAD+ redox reactions are 
vital in energy production pathways such as glycolysis, 
oxidative phosphorylation and fatty acid oxidation. 
Typically NAD+ is predominantly found in its oxidised 
form with NAD/NADH ratios varying from 10/1 to 700/1 
and a total cellular concentration thought to be estimated 
between 0.3–1.0 mM in mammalian cells (Veech  et  al. 
1972, Casazza & Veech 1986). Alternatively, NAD+ can 
be phosphorylated to NADP+ by NAD kinase and likewise 
this also exists in its reduced form NADPH. NADP(H) 
concentrations are estimated at 10% of total NAD(H) 
levels (Veech et al. 1972, Casazza & Veech 1986). NADPH 
acts as an essential reducing agent aiding many anabolic 
pathways including nucleic acid and lipid biosynthesis 
(Berger et al. 2004, Tedeschi et al. 2016).
More recently, NAD+ has been recognised as an 
important signalling molecule that is consumed upon the 
activity of several enzymes including sirtuins (SIRTs), poly-
ADP-ribose polymerases (PARPs) and cyclic ADP-ribose 
synthases (cADPRSs) (Houtkooper et al. 2010, Dolle et al. 
2013). This new found purpose highlighted that NAD+, 
previously thought of as a stable molecule, is actually in 
continuous turnover and tightly regulated to maintain 
metabolic homeostasis. In fact, with approximately 2.5 
ATP molecules formed per pair of electrons donated by 
NADH in the electron transport chain, and an estimated 
80 kg of ATP turned over by an adult male each day, it is 
predicted as much as 30 kg NADH is generated every day, 
reinforcing the need for regulated maintenance of NAD(H) 
biosynthetic pathways (Kornberg 1991, Walsh et al. 2018).
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SIRTs are important for metabolic energy control, 
whereby induction of SIRTs results in posttranslational 
modifications, such as deacetylation of substrate lysine 
residues, typically in an NAD+-dependent manner 
(Dali‐Youcef  et  al. 2007, Houtkooper  et  al. 2012). 
Following activation, generally at times of energy 
deficit and concomitant with a rise in NAD+ content, 
SIRT activity (most notably SIRT1 and SIRT3) leads to 
metabolic adaptation in favour of more efficient ATP 
generation for example by enhancing mitochondrial 
content and capacity (Rodgers  et  al. 2005, Rodgers & 
Puigserver 2007, Feige et al. 2008, Canto et al. 2009, 2010, 
Hirschey et al. 2010, Jing et al. 2011, 2013). In models 
of SIRT1 and SIRT3 deficiency, metabolic impairments 
were detected particularly following metabolic challenge 
(Boily  et al. 2008, Hirschey et al. 2010, Xu  et al. 2010, 
Kendrick et al. 2011, Purushotham et al. 2012, Jing et al. 
2013). However, muscle and liver-specific models of 
SIRT3 deficiency did not exhibit a metabolic phenotype 
despite detectable hyperacetylation of mitochondrial 
proteins; this was potentially explained by compensation 
by SIRT3 activity in other tissues or key residues 
unaffected by hyperacetylation (Fernandez-Marcos et al. 
2012). PARPs, on the other hand, belong to the ADP-
ribosyltransferase family and sequentially transfer 
ADP-ribose from NAD+ to proteins, leading to poly ADP-
ribosylation (PARylation) (Decker & Muller 2002, Luo 
& Kraus 2012). Seventeen different PARPs have been 
identified in mammals and although they have been 
recognised to have numerous distinct functions the 
most well-described function of PARP activity is during 
DNA repair processes (Decker & Muller 2002). PARP1 
is activated by DNA damage and PARylation at these 
sites leads to recruitment and induction of proteins 
essential to DNA repair processes (El-Khamisy  et  al. 
2003, Mao et al. 2011, Luo & Kraus 2012). Although not 
necessarily NAD+ dependent, PARP signalling consumes 
large quantities of cellular NAD+ and exhibits a higher 
affinity for NAD+ than SIRTs therefore prolonged PARP 
activation may deplete cellular NAD+ levels (Charron & 
Bonner-Weir 1999, Ha & Snyder 1999, Kauppinen et al. 
2013). Though less well defined, the cADPRSs CD38 
and CD157 have also been identified as major NAD+-
consuming enzymes (Aksoy  et  al. 2006, Graeff  et  al. 
2009). They are transmembrane enzymes and play vital 
roles in several physiological mechanisms including 
maintaining calcium (Ca2+) homeostasis and immune 
function (De Flora et al. 1998, Graeff et al. 2009).
NAD+ compartmentalisation
Distinct subcellular NAD(H) pools were first proposed 
due to organelle-specific expression of different NAD+-
generating and -consuming enzymes (VanLinden  et  al. 
2015, Cambronne  et  al. 2016). Technical advances, 
most recently in the form and use of fluorescent NAD+ 
biosensors, have provided support for the idea of 
compartmentalisation of independent NAD+ pools within 
cells. Nucleic and cytosolic NAD+ levels are typically 
found to be interchangeable with NAD+ able to pass 
freely through nuclear membrane pores. Conversely, 
the mitochondrial membrane is impermeable to NAD+ 
and NADH thus mitochondrial NAD+ levels fluctuate 
independently (Cambronne et al. 2016). A mitochondria-
specific pool of NAD+ would seem to enable cells to defend 
oxidative phosphorylation capacity against transient 
cytoplasmic/nuclear NAD+ depletion (Pittelli et al. 2010). 
NAD+ pool size varies in different tissues, for example, 
cardiac myocytes have an expectedly higher percentage 
of mitochondrial NAD+ compared to cytosolic yet 
cell types including astrocytes and hepatocytes have 
a more substantial cytosolic pool (Alano  et  al. 2007). 
These differences would seem to reflect the demand on 
oxidative capacity and function of the different cells. 
Despite individual NAD+ pools, vital crosstalk exists 
between compartments. Glyceraldehyde-3-phosphate 
and malate–aspartate shuttles allow the transfer of 
electrons from cytosolic NADH into the mitochondria and 
oxidised NAD+ is released into the cytosol. Thus, cytosolic 
NAD+ concentrations are an important determinant of 
mitochondrial NADH flux; meaning major loss of NAD+, 
especially in cells predominantly using carbohydrates as 
a fuel source, would eventually lead to impaired energy 
production and ultimately cell death (Easlon et al. 2008).
Established NAD+ biosynthesis pathways
In mammalian cells, a number of NAD+ biosynthesis 
pathways have been established. These pathways can 
synthesise NAD+ de novo from l-tryptophan or from the 
salvage of vitamin B3 NAD+ precursors nicotinic acid (NA), 
nicotinamide (NAM) and nicotinamide riboside (NR) 
(Houtkooper et al. 2010, Dolle et al. 2013) (Fig. 1). The NAD+ 
biosynthesis pathways can be grouped into two distinct 
routes described as ‘amidated’ or ‘deamidated’ (Mori et al. 
2014). De novo synthesis from tryptophan and NA salvage 
is grouped into the ‘deamidated’ pathway and shares a 
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final rate-limiting amidation enzyme NADsynthase1 
(NADSYN) (Preiss & Handler 1958). Conversely, NAM 
and NR contain an amide group and therefore follow 
the ‘amidated’ route to NAD+ (Bieganowski & Brenner 
2004, Tan et al. 2013, Mori et al. 2014) (Fig. 1). The high 
turnover of NAD+ in most cell types means that a major 
disruption to these biosynthesis pathways could lead to a 
severe depletion of cellular NAD+ levels and, if sustained, 
ultimately lead to cell death (Hasmann & Schemainda 
2003, Yang et al. 2007).
De novo biosynthesis
De novo NAD+ biosynthesis predominantly begins 
with the dietary amino acid l-tryptophan. Initially, 
N-formylkynurenine is generated from tryptophan by 
the rate-limiting enzyme indoleamine 2,3-dioxygenase or 
alternatively tryptophan 2,3-dioxygenase. Next, a sequence 
of four enzymatic reactions convert N-formylknurenine 
to α-amino-β-carboxymuconate-ε-semialdehyde (ACMS) 
(Nikiforov et al. 2011). ACMS can either undergo complete 
oxidation or spontaneous cyclisation to produce quinolinic 
acid. The conversion of quinolinic acid to nicotinic acid 
mononucleotide (NAMN) is catalysed by quinolinate 
phosphoribosyl-transferase and NAMN is subsequently 
converted to nicotinic acid adenine dinucleotide (NAAD) 
by the ubiquitously expressed enzyme nicotinamide 
mononucleotide adenylyltransferase (NMNAT) (Nikiforov 
et al. 2011). Finally, NAAD is amidated to NAD+ in an ATP-
dependent reaction via glutamine-dependent NADSYN 
activity (Hara et al. 2003).
Vitamin B3 salvage pathways
Although de novo biosynthesis is a major route to NAD+ in 
the liver (Bender et al. 1982, Bender & Olufunwa 1988), 
the majority of cellular NAD+ content in other tissues, 
and to some degree in the liver, is attributed to salvage 
pathways which resynthesise NAD+ from the vitamin B3 
precursor molecules NA, NAM and NR, also known as 
niacins (Mukherjee  et  al. 2017). These precursors share 
similar chemical structures and can either be absorbed 
from the diet or found as a consumed NAD(P)(H) 
metabolites (Gross  et  al. 1998, Bieganowski & Brenner 
2004, Khan et al. 2006).
NA can be salvaged to NAD+ via the Preiss–Handler 
pathway; initially NA is converted to NAMN in a reaction 
is catalysed by NA phosphoribosyltransferase (NAPT) 
with 5-phospho-α-d-ribose-1-diphosphate as its substrate 
(Preiss & Handler 1958). The pathway then converges 
with the de novo biosynthesis pathway; thus, NAMN is 
converted to NAAD by NMNAT activity and finally to 
NAD+ by NADSYN (Preiss & Handler 1958). Mammalian 
NADSYN is a homohexameric protein localised to the 
Figure 1
Mammalian NAD+ biosynthesis pathways. An 
illustration of mammalian NAD+ biosynthesis 
pathways with exogenous precursor 
supplementation strategies outlined in green 
with dashed arrows). NAD+ can be generated 
from Trp de novo with multiple enzymatic 
reactions leading to the production of quinolinic 
acid (QA), which is then converted to nicotinic 
acid mononucleotide NaMN by 
QA-phosphoribosyltransferase (QPRTase) and 
then to nicotinic acid dinucleotide (NaAD) by 
nicotinamide mononucleotide 
adenylyltransferase (NMNAT) activity, before the 
final conversion to NAD+ by NAD synthase 
(NADSYN). Alternatively NAD+ can be salvaged 
from precursors and nicotinic acid (NA) nicotinic 
acid riboside (NaR) by NA 
phosphoribosyltransferase (NAPRT) nicotinamide 
riboside kinases (NRK1/2) respectively to NaMN 
and finally NDA+ by NMNAT. Alternatively, most 
tissues rely on the amidated routes for NAD+ 
biosynthesis (outlined in red box). Here, 
nicotinamide riboside (NR) and nicotinamide 
(NAM) are salvaged by NRKs and nicotinamide 
phosphoribosyltransferase (NAMPT) respectively 
to nicotinamide mononucleotide (NMN) and 
ultimately converted to NAD+ by NMNAT.
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cytosol. Its enzymatic activity requires co-substrates 
ATP and glutamine to convert NAAD to NAD+ and 
releases AMP, PPi and glutamic acid in the process (Mori 
et  al. 2014). NADSYN is the final rate-limiting step of 
both the de novo and Preiss–Handler pathway and thus 
essential for the generation of NAD+ via these routes. 
NADSYN expression and activity has been shown to be 
both organism and tissue specific. Some microorganisms 
including Mycobacterium tuberculosis are dependent on 
NADSYN for NAD+ biosynthesis, which consequently 
makes it a potential antibacterial target, whereas 
others use alternative pathways for NAD+ biosynthesis 
(Boshoff et al. 2008, De Ingeniis et al. 2012). The rate of 
NADSYN enzyme activity has been determined in a range 
of mouse tissues with highest activity levels found in 
liver and kidney tissue, whereas activity was minimal in 
brain homogenates and undetectable in lung and skeletal 
muscle tissues suggesting NAD+ biosynthesis via the 
de novo and Preiss–Handler pathways is limited to certain 
tissues (Mori et al. 2014).
Alternatively, NAD+ can be salvaged from NAM by 
the nicotinamide phosphoribosyltransferase (NAMPT) 
pathway (Tan et  al. 2013). In this pathway, NAMPT 
catalyses the first rate-limiting reaction that converts 
substrates NAM and 5′-phosphoribosyl-1-pyrophosphate 
(PRPP) to nicotinamide mononucleotide (NMN) in an 
ATP-dependent reaction. Then, NMNAT activity allows the 
conversion of NMN to NAD+ (Garten et al.). Importantly, 
NAD+ consumption by SIRT and PARP activity results in the 
release of NAM as a reaction product; therefore, salvage by 
NAMPT provides a central cellular NAD+ recycling loop. 
Recycling of NAD+ via this pathway is tightly regulated in 
order to sustain appropriate NAD+ homeostasis, with both 
NAMPT expression and activity shown to be modulated by 
cellular NAD+ levels and SIRT activity negatively regulated 
by NAM levels (Bitterman et al. 2002).
NAMPT is a dimeric type II phosphoribosyltransferase 
that is highly conserved and expressed in nearly all the 
tissues and cells examined suggesting a vital role for 
NAMPT activity in normal cell function (Wang  et  al. 
2006, Garten  et  al. 2015). Initially, it was termed 
pre-B cell colony-enhancing factor (PBEF) due to its 
proposed cytokine function (Samal  et  al. 1994); it was 
then determined to be a hormonal factor, and renamed 
visfatin, that supposedly exerted insulin mimetic effects 
(Fukuhara  et  al. 2005) that have since been found to 
be unverified (Harasim  et  al. 2011). NAMPT is both an 
intracellular and extracellular protein, the intracellular 
isoform is predominantly localised to the cytosolic and 
nucleic fractions (Kitani et al. 2003, Revollo et al. 2007). 
Within several cell types NAMPT has been shown as a 
vital enzyme for maintaining cellular NAD+ and energy 
homeostasis by recycling NAM to NAD+ (Yoon et al. 2015, 
Frederick  et  al. 2016, Lin  et  al. 2016, Agerholm  et  al. 
2018, Nielsen  et  al. 2018). Pharmacological inhibition 
of NAMPT using the potent inhibitor FK866 results in 
NAD+ depletion and for cells that predominantly rely on 
this pathway for NAD+ salvage can result in cell death 
(Hasmann & Schemainda 2003, Tan et  al. 2013). The 
importance of extracellular NAMPT (eNAMPT) remains 
unclear. It has been proposed that extracellular activity 
may be part of a wider pathological process whereby 
ATP and PRPP – both required for NAM salvage and 
normally found at low levels in the plasma – are released 
from dying cells into the circulation and drive enzyme 
activity (Hara et al. 2011, Garten et al. 2015). In diabetes, 
an association between eNAMPT and pro-inflammatory 
responses including the induction of inducible nitric 
oxide synthase has been reported (Kieswich et al. 2016).
The emergence of the NRK pathway to NAD+
In healthy cells, the vitamin B3 NAD+ precursors are 
essential for replenishing NAD+ for the maintenance of 
appropriate cellular NAD+ levels in all compartments 
supporting energy homeostasis (Bender & Olufunwa 1988, 
Bogan & Brenner 2008, Dolle et al. 2013). The significance 
of a requirement for vitamin B3 was first delineated in 
the disease pellagra, a disorder of B3 deficiency, and since 
then, increasing evidence has shown that a breakdown in 
the balance of NAD+ generation vs NAD+ consumption is 
a common factor in numerous morbidities (Pitche 2005).
In 2004, a new pathway to NAD+ synthesis 
was determined by Charles Brenner following the 
identification of nicotinamide riboside kinase 1 (Nrk1) in 
yeast and subsequent human homologs NRK1 and NRK2 
(Bieganowski & Brenner 2004, Tempel et al. 2007). In the 
initial step of the pathway, NRK activity catalyses the 
phosphorylation of NR to nicotinamide mononucleotide 
(NMN) (Tempel et  al. 2007), which is subsequently 
converted to NAD+ by NMNAT (Fig.  2) (Bieganowski 
& Brenner 2004). Alternatively, NRK activity can 
phosphorylate nicotinic acid riboside (NaR) to nicotinic 
acid mononucleotide (NaMN), which is then converted 
to NaAD and finally NAD+ by NMNAT and NADSYN, 
respectively (Tempel et al. 2007). The discovery of the NRK 
enzymes stemmed from previous work that showed NR, as 
a novel NAD+ precursor, could extend the lifespan of yeast 
through the induction of Sir2 in an NAD+-dependent 
manner (Bieganowski & Brenner 2004). Since then, the 
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mounting evidence towards the beneficial effects of using 
NAD+ precursors, and in particular, NR and NMN, has 
led to the emergence of the NRK enzymes as therapeutic 
targets. Although the NRK enzymes were identified as 
an alternative salvage pathway to NAD+ (Bieganowski & 
Brenner 2004), investigations have only recently begun 
to define the importance of NRK1 and 2 in terms of NAD+ 
metabolism and beyond.
NRK1 and 2 (encoded by Nmrk1 and Nmrk2 genes, 
respectively) both exhibit a high affinity for NR, yet, 
their substrate specificity differs (Fig.  1). With ATP 
as a co-substrate NRK1 has a KM of 0.088 mM for NR, 
whereas NRK2 has a KM of 0.19 mM (Tempel et  al. 
2007). Furthermore, NRK1 can also use GTP (guanosine 
triphosphate) as a co-substrate for the phosphorylation of 
NR yet NRK2 is restricted to ATP (Tempel et al. 2007, Dölle 
& Ziegler 2009). The enzyme turnover of NR to NMN with 
ATP has also been estimated; here, the Kcat was found to 
be around 0.6/S for NRK1 and 0.75/S for NRK2 (Tempel 
et al. 2007). On the other hand, NRK1 and NRK2 exhibit 
a similar affinity for NaR with a KM of 0.051 mM and 
0.063 mM, respectively (Fig. 1 and Table 1). Further kinetic 
studies using a pyruvate kinase/lactate dehydrogenase-
coupled enzyme assay confirmed these findings with 
the KM of NRK1 and 2 found to be in the micromolar 
range and NRK1 again exhibiting a higher affinity for 
NR. Interestingly, here they also showed that NRK2 had 
a 10-fold higher affinity than NRK1 for uridine; yet, they 
share a similar affinity for cytidine (Dölle & Ziegler 2009).
In mammalian tissues, NRK1 is ubiquitously 
expressed, whereas NRK2 has been shown to be muscle 
specific with expression more predominant in skeletal 
muscle compared to cardiac (Fletcher et al., Ratajczak et al. 
2016). Initial studies in zebrafish identified that Nrk2b is 
a vital component for musculoskeletal development. In 
Nrk2b-deficient zebrafish muscular abnormalities were 
identified, including irregular laminin polymerisation at 
myotendinous junctions and abnormally long muscle 
fibres that have elongated into adjacent myotomes 
(Goody  et  al. 2010). These changes were caused by 
aberrant cell matrix adhesion complex signalling driven 
by atypical localisation of Paxillin. It is proposed that the 
Nrk2b homolog is specifically localised to myotendinous 
junctions to provide a local NAD+ supply, and this may 
potentially explain why the alternative Nrk homologs are 
unable to compensate. Importantly, this phenotype was 
rescued following administration of NAD+ demonstrating 
that the effects were NAD+ dependent and that Nrk2b 
plays a central role in zebrafish NAD+ biosynthesis 
(Goody et al. 2012).
However, murine NRK1 and NRK2 loss-of-function 
models do not exhibit any gross phenotypic abnormalities, 
with steady state NAD+ levels unaffected, at least in the 
tissues that have been examined (liver, skeletal muscle, 
brown adipose and kidney) (Fletcher et al., Ratajczak et al. 
2016). Thus, despite the NRK salvage pathway being highly 
conserved (Bieganowski & Brenner 2004), it appears to 
play a redundant role in basal murine metabolism; with 
most tissues examined reliant on the NAMPT salvage 
pathway to maintain NAD+ levels (Fletcher et al., Tan et al. 
2015, Frederick et  al. 2016, Stromsdorfer  et  al. 2016, 
Zhang  et  al. 2017, Agerholm et  al. 2018, Nielsen  et  al. 
2018). The differences seen between zebrafish and murine 
models following loss of NRK function may be attributed 
to an absence of alternative NAD+ biosynthesis pathways 
in zebrafish skeletal muscle tissue. Although NRK1 and 
NRK2 do not appear critical in mice for endogenous 
NR salvage to NAD+, their activity has been determined 
essential for the utilisation of exogenous NR and, more 
surprisingly, NMN. Following supplementation, it is 
Figure 2
NRK1/2 mediated NAD+ biosynthesis pathway. 
Nicotinamide riboside (NR) is metabolised by 
nicotinamide riboside kinase (NRK1/2) to 
nicotinamide mononucleotide (NMN) and 
subsequently converted to NAD+ by NMN-
adenylyltransferase (NMNAT) activity.
Table 1 Estimated NRK1 and NRK2 enzyme kinetics and 
substrate specificity (Tempel et al. 2007).
 
Substrate
 
KM (mM)
 
Kcat (/S)
 
Kcat/KM (/S/M)
Substrate 
specificity
NRK1
 NR + ATP 0.088 0.6 6800 ATP, GTP
 NR + GTP 0.068 0.34 5000
 NaR + ATP 0.051 0.21 4100
NRK2
 NR + ATP 0.19 0.75 3900 ATP 
  NR + GTP 30 1.7 57
 NaR + ATP 0.063 0.34 5400
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thought NR is transported into cells via the nicotinamide 
riboside transporter orthologue of the yeast Nrt1 protein 
(Belenky et al. 2011).
Without expression of the NRK enzymes in tissues, the 
NAD+-boosting effects of NR and NMN supplementation 
is blocked, whilst expression of alternative NAD+ 
biosynthesis enzymes remains comparable to WT mice 
(Fletcher et  al., Ratajczak et  al. 2016). In addition, the 
NAD+ boosting effect of NR and NMN supplementation 
following NAMPT inhibition by FK866 in muscle and 
hepatic cells is comparable to that of untreated cells. 
Interestingly, phosphorylation of NR by NRK1 appears 
preferred to NRK2 even in skeletal muscle where Nmrk2 
is specifically expressed and found at substantially 
higher mRNA levels than Nmrk1 (Fletcher et  al.). This 
firstly shows the NRK enzymes exclusively metabolise 
NR, but it also suggests that NMN must be converted 
to NR to enter the cell and then be re-phosphorylated 
intracellularly back to NMN (Fletcher et  al., Ratajczak 
et al. 2016). Previous studies have shown that NMN can be 
dephosphorylated by cytosolic 5′-nucleotidases and thus 
it has been postulated that NMN is dephosphorylated to 
NR extracellularly by the cell membrane protein CD73 
(also known as ecto-5-nucleotidase) and then imported 
into the cell (Kulikova et al. 2015).
Organism and tissue NAD+ salvage 
pathway specificity
NAD+ biosynthesis and salvage enzymes are evolutionarily 
conserved from bacteria to mammals yet in some 
organisms certain pathways are preferred (Berger et  al. 
2004). For example, in mammals, the NAMPT-mediated 
NAD+ biosynthesis pathway is essential for maintaining 
adequate cellular NAD+ levels and complete absence of the 
Nampt gene is embryonically lethal (Garten et  al. 2015, 
Tan et  al. 2015, Zhang et  al. 2017). Despite being well 
conserved in mammals, the NRK enzymes appear non-
essential yet some microorganisms rely on NRK activity 
to salvage NAD+ (Fletcher et  al., Gazzaniga  et  al. 2009, 
Ratajczak et  al. 2016). For example, the multifunctional 
protein NadR is expressed in microorganisms and 
exhibits both ribosylnicotinamide kinase (RNK) activity 
to phosphorylate NR or NaR, as well as Nmnat activity 
for NAD+ biosynthesis. In Haemophilus influenzae, NadR 
activity is essential for growth yet in microorganisms such 
as Salmonella enterica serovar Typhimurium, NadR activity 
is present but not vital (Kurnasov et al. 2002).
The relative importance and tissue specificity of the 
different precursor molecules in NAD+ replenishment 
in vivo is becoming well defined in some tissues but is 
unclear in others. For example, de novo biosynthesis is 
thought to be the preferred route for NAD+ biosynthesis 
in the liver (Bender et  al. 1982, Bender & Olufunwa 
1988), with hepatocyte NAD+ content potentially more 
resistant to loss of NAMPT function compared to tissues 
such as muscle and fat (Schuster  et  al. 2015, Ratajczak 
et al. 2016). With that said, changes to NAMPT expression 
in hepatocytes has been shown to alter NAD+ content 
and induce physiological changes highlighting that 
the NAMPT salvage pathway still plays an important 
role in hepatocyte NAD+ biosynthesis (Zhou  et al. 2016, 
Mukherjee et al. 2017, Zhang et al. 2017). In the majority 
of other tissues investigated to date, it is thought that 
cellular NAD+ is predominantly attributed to NAD+ salvage 
pathways using vitamin B3 precursors found in the diet or 
as consumed NAD+ metabolites (Mori et al. 2014). In many 
of these tissues, direct recycling of NAM is believed to be 
preferred over NA salvage; with only transient increases in 
NAD+ following intraperitoneal injection of NA compared 
to stable increases following NAM administration (Collins 
& Chaykin 1972). This is further supported by evidence 
showing NADSYN activity, the final rate-limiting enzyme 
in the NA salvage pathway appears inferior to the final 
rate-limiting step of the amidated pathways (Mori et  al. 
2014). In mammalian tissue, NR salvage to NAD+ via the 
NRK enzymes is not essential and appears limited to NR 
availability with endogenous NR levels seemingly low 
in tissues yet exogenous delivery of NR appears highly 
effective in enhancing NAD+ directly through NRK activity 
(Fletcher et al., Ratajczak et al. 2016).
Regulation of the NRK enzymes
Aside from the requirement for NRK1 and/or NRK2 to 
enhance cellular NAD+ content following exogenous 
NR or NMN supplementation, recent data suggest NRK2 
may play a an important endogenous role in adaptation 
to metabolic and energy stress. The regulation of NRK2 
has been determined in pathophysiological settings and 
in response to NAD+ insufficiency (Fig. 3 – upper panel) 
(Fletcher et  al., Sasaki  et  al. 2006, Lavery  et  al. 2008, 
Aguilar  et  al. 2015, Xu  et  al. 2015, Diguet  et  al. 2017). 
Following injury to dorsal root ganglion neurons, Nmrk2 
was the most upregulated NAD+ biosynthetic gene (by 
over 20-fold), which is surprising considering Nmrk2 
expression is typically absent or detected at low levels 
in central nervous system tissues (Sasaki et  al. 2006). 
In addition, in a mouse model of traumatic lower limb 
muscle injury, Nmrk2 was again found to be significantly 
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upregulated (three-fold) at 24 h post injury (Aguilar 
et  al. 2015). Mice with a loss of hexose-6-phosphate 
dehydrogenase (H6PDH) function, an ER-based enzyme 
required for local NADPH generation, manifest with severe 
muscle myopathy and on transcriptional analysis Nmrk2 
expression was the most dysregulated gene (upregulated 
by >60-fold mRNA level) (Lavery et al. 2008). Furthermore, 
Nmrk2 mRNA expression was substantially induced 
(>80-fold) in models of lethal cardiomyopathy (Xu et al. 
2015). In this model, administration with NR was able to 
increase lifespan of these mice by 50% suggesting that this 
induction of Nmrk2 in cardiac tissue is to support NAD+ 
generation (Xu et  al. 2015). The hypothesis of Nmrk2 
induction to support NAD+ biosynthesis during injury or 
potentially extreme energetic stress is further supported by 
its induction during NAD+ depletion. For example, loss of 
NAD+ by pharmacological inhibition of NAMPT also leads 
to an induction in Nmrk2 expression, which is normalised 
when NAD+ levels are restored with NR supplementation 
(Fletcher et al.).
More recently, in two murine models of the failing 
heart that cause dilated cardiomyopathy or cardiac 
hypertrophy, a significant induction of NRK2 – by 40-fold 
and 4-fold respectively – was determined (Diguet et  al. 
2017). Conversely, NAMPT expression was downregulated 
and NAD+ levels were reduced in both models. Similar 
changes were seen in human failing hearts (Diguet et al. 
2017). These findings led to the proposal by Diguet et al. 
that in NAD+ deficiency, NRK2 may be induced to aid 
NAD+ biosynthesis. Circulating NR levels are thought to 
be low or absent (Trammell et al. 2016a) but importantly 
upon dietary NR supplementation protective effects to 
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Figure 3
Proposed NRK expression in disease and potential therapeutic interventions. Adaptive NRK expression (Top) has been identified in numerous 
pathological scenarios where commonly an induction of NRK2 expression has been seen with loss of NAD+ and altered activity of NAD+-consuming 
enzymes. Supplementation with NAD+ precursors nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) (bottom), both requiring NRK 
activity, can elevate intracellular NAD+ and has been shown to result in many health benefits in numerous rodent models.
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cardiac function were seen (Diguet et al. 2017). They went 
on to describe the first mechanisms regulating mammalian 
NRK2 expression. Upregulation of Nmrk2, in response to 
ATP and NAD+ depletion, suggested Nmrk2 is controlled 
by energy metabolism signalling pathways (Diguet et al. 
2017). Supporting this hypothesis, they found that Nmrk2 
was regulated during energetic stress in an AMP-kinase 
and peroxisome proliferator-activated receptor α (PPARα)-
dependent manner in cardiac cells (Diguet et al. 2017).
Intracellular NAD+ concentrations, as well as Sirt1 and 
Nampt gene expression, have been shown in the liver to 
be regulated by the circadian clock oscillating in a 24-h 
rhythm (Nakahata  et  al. 2009). The expression of these 
genes and NAD+ levels are impacted by circadian clock gene 
loss of function and in reverse pharmacological inhibition 
of NAMPT and loss of NAD+ impacted on circadian gene 
expression profiles (Nakahata et  al. 2009). In addition 
high-fat diet-fed mouse livers saw remodelling of circadian 
clock expression and ablation of circadian NAD+, further 
linking the importance of NAD+ regulation for appropriate 
circadian clock functioning (Nakahata et al. 2009, Eckel-
Mahan  et  al. 2013). Less is known about the circadian 
regulation of Nmrk1 and 2. Nmrk1 was recently shown to be 
circadian regulated in mouse liver tissue and interestingly, 
like Nampt, Nmrk1 expression was dysregulated in clock-
disrupted mice (Mauvoisin et al. 2017).
NAD+ precursors as therapeutic interventions
NAD+ has long been associated with disease with symptoms 
of pellagra first described in the 1800s (Pitche 2005). 
Pellagra is most commonly caused by malnutrition – more 
specifically a deficiency in vitamin B3 NAD+ precursors – 
and is classically characterised by the triad of symptoms; 
dermatitis, diarrhoea and dementia. Pellagra is historically 
associated with diets rich in maize, which presents little 
nutritional value and it was later found that dietary 
supplementation with NAD+ precursors successfully treated 
pellagra (Pitche 2005, Naveen et al. 2013).
Since the role of NAD+ as a central metabolic signalling 
molecule was discovered, there has been a substantial 
number of studies associating NAD+ availability to 
metabolic health. A decline in NAD+ in multiple tissues 
and cell types has been linked to the pathophysiology 
of ageing and chronic disease states including type II 
diabetes, neurodegeneration, liver disease and cachexia 
(Koltai et al. 2010, Braidy et al. 2011, Yoshino et al. 2011, 
Massudi et al. 2012, Gomes et al. 2013, Long et al. 2015, 
Camacho-Pereira et al. 2016, Mills et al. 2016, Zhou et al. 
2016). Many of these studies implicate reduced SIRT 
expression and/or activity following a loss of NAD+ and 
consequently the activity of key SIRT-mediated targets 
(Koltai et al. 2010, Braidy et al. 2011, Yoshino et al. 2011, 
Massudi et al. 2012, Gomes et al. 2013, Long et al. 2015, 
Camacho-Pereira et  al. 2016, Zhou et  al. 2016). Loss of 
NAD+ in many of these scenarios may, at least in part, 
be attributed to elevated PARP activity (Pillai et al. 2005, 
Braidy et  al. 2011, Massudi et  al. 2012, Lehmann  et  al. 
2016). With increased DNA damage, a hallmark factor of 
ageing and a consequence of chronic disease, increased 
PARP activity to induce DNA repair processes can be 
detrimental to metabolic homeostasis with a decline to 
cellular NAD+ availability leading to reduced SIRT activity 
(Decker & Muller 2002, Bai  et  al. 2011a, Massudi et  al. 
2012). The importance of NAD+-consuming enzyme 
crosstalk has previously been established through models 
of PARP excess and deletion. These models demonstrate a 
concomitant decrease in NAD+ and SIRT activity following 
PARP overexpression and an increase in NAD+ content 
and SIRT-mediated signalling when PARP activity is 
inhibited (Mangerich et al. 2010, Bai et al. 2011a,b, Luo & 
Kraus 2012, Mohamed et al. 2014). PARP inhibitors have 
already shown promise as anticancer agents and now may 
also be valuable therapeutics against metabolic disease, 
with PARP inhibition resulting in enhanced oxidative 
metabolism in mouse models (Bai et al. 2011a,b, To et al. 
2014). Recent studies have also implicated CD38 in age-
related mitochondrial dysfunction. An increase in CD38 
expression was determined in metabolic tissues such as 
liver, adipose and muscle. Detrimental effects of CD38 in 
ageing, mediated via a SIRT3 mechanism, were to some 
extent reversed in CD38 loss-of-function mouse models 
(Camacho-Pereira et al. 2016).
The knowledge that enhancing NAD+ can induce 
positive metabolic effects mediated through the induction 
of SIRT has additionally resulted in a vast array of 
studies looking at the efficacy of using NAD+ precursors 
to boost NAD+ (Mouchiroud  et  al. 2013, Fang  et  al. 
2017, Rajman  et  al. 2018). NA derivatives have been 
used clinically for many years, notably in treatment of 
hypercholesterolemia; however, action on the GPR109A 
receptor causes undesirable flushing side effects in a 
large proportion of patients and ultimately leads to poor 
compliance (Taskinen & Nikkila 1988, Gille et al. 2008, van 
de Weijer et al. 2015). There has since been major interest 
in the use of alternative NAD+ precursors that do not 
activate the GPR109A. Although nicotinamide has been 
shown to be effective in boosting NAD+ in tissues, concerns 
regarding the requirement of high doses, which may exert 
an inhibitory effect on SIRT activity and reduce efficacy 
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(Collins & Chaykin 1972, Bender & Olufunwa 1988, 
Bitterman et al. 2002, Liu et al. 2009, Mitchell et al. 2018), 
have led to a surge of research focussing on the therapeutic 
potential of NR and NMN (Elhassan et al. 2017).
Both NR and NMN have been shown as effective 
NAD+ enhancers in numerous models following 
supplementation without any notable adverse effects 
reported to date (Yoshino et al. 2011, Cantó  et al. 2012, 
Khan et al. 2014, Mills et al. 2016, Trammell et al. 2016b, 
Uddin  et al. 2016, Wang  et al. 2016, Zhang  et al. 2016). 
The number of studies investigating their therapeutic 
potential has grown rapidly in recent years. Although 
these studies have often focussed on one or the other 
compound, similar and overlapping effects of either NR or 
NMN supplementation have been reported (Fig. 3 – lower 
panel). These include NR-mediated NAD+ repletion in 
ageing mice protecting against muscle degeneration, and 
similarly delayed muscle stem cell senescence in models 
of muscular dystrophy through improved mitochondrial 
function resulting in enhanced regenerative capacity 
and more favourable phenotypes (Zhang et  al. 2016). 
Importantly, the beneficial regenerative effects of NR 
extended to neural and melanocyte stem cells where 
it was shown to delay senescence and extend life 
span (Zhang et  al. 2016). NMN supplementation also 
exhibited positive effects on neurogenesis in aged mice 
by preserving the neural stem/progenitor cell pool (Stein 
& Imai 2014). In models of cardiac pathology including 
ischaemia and reperfusion, heart failure and hypertrophy 
supplementation with either NMN or NR has resulted in 
improved outcomes (Yamamoto et al. 2014, Diguet et al. 
2017). In metabolic diseases of obesity, diabetes and non-
alcoholic fatty liver disease (NAFLD) protective effects 
of exogenous NR or NMN delivery include enhanced 
metabolic flexibility, mitochondrial function, improved 
glucose tolerance, reduced weight gain and prevention of 
hepatic steatosis and other pathological factors of NAFLD 
(Yoshino et  al. 2011, Cantó et  al. 2012, Trammell  et  al. 
2016b, Zhou et al. 2016, Shi et al. 2017) (Fig. 3). There have 
been many more studies recently published investigating 
the in vivo effects of NR and NMN supplementation in 
a variety of disease models, and a more detailed analysis 
of these has been well described in a number of recent 
reviews (Fang et al., Rajman et al. 2018).
Currently, the majority of work looking at the benefits 
of vitamin B3 supplementation has been carried out using 
animal models; thus, the translational potential to humans 
is still unclear. Currently, a number of clinical trials 
focussing on NR and NMN supplementation have recently 
been completed or are still ongoing. The first clinical study 
with NR – a double-blind, randomised pharmacokinetic 
study with 12 participants – found a single oral dose of 
1000 mg NR raised circulatory NAD+ levels by 2.7-fold; 
interestingly, NAD+ metabolomics also identified NAAD 
as a highly sensitive biomarker for NAD+ (Trammell et al. 
2016a). In another non-randomised clinical study with 
eight subjects, a dose-dependent increase in NAD+ was 
found with 250–1000 mg/day NR was orally administered 
over 9 days with a maximal two-fold increase seen in NAD+ 
(Airhart et al. 2017). An 8-week double-blind, randomised 
clinical trial (n = 118) assessing the efficacy and safety 
of repeat dose NR in combination with the polyphenol 
molecule pterostilbene, collectively known as NRPT, 
dosed at either 250 mg NR/50 mg PT or 500 mg NR/100 mg 
PT vs a placebo control group has been conducted 
(Dellinger et al. 2017). This study provided positive results 
regarding the safety of repeat dose NRPT and also showed 
a significant increase in whole blood NAD+. In addition, 
potentially positive effects were observed regarding liver 
function, which may become more apparent in larger 
scale clinical trials (Dellinger et  al. 2017). In addition, 
an in-depth analysis of chronic NR supplementation 
(500 mg, twice/day) has recently been investigated in a 
randomised 6-week, double-blind, placebo-controlled, 
crossover clinical trial in healthy middle-aged to older 
adults (n = 24). The results from this latest trial further 
supported previous studies, showing that at this dose, 
chronic NR was well tolerated by subjects and was also 
able to enhance NAD+ levels of blood cells (Martens et al. 
2018). Interestingly, the study also demonstrated some 
positive trends following NR supplementation in terms 
of cardiovascular health including NR potentially 
reducing systolic blood pressure and arterial stiffness (de 
Picciotto et al. 2016). Again, larger scale clinical trials are 
now required to establish the potential of NR to exert 
beneficial effects on these cardiovascular parameters and 
beyond. There are several ongoing clinical studies that 
are currently further assessing the safety, efficacy and 
impact of either NR or NMN supplementation on a wide 
range of health parameters including vascular endothelial 
function, immune function, kidney function, muscle 
mitochondrial function, cognitive function and energy 
metabolism (see clinicaltrials.gov). Although there is still 
much to learn regarding the clinical impact of NR and 
NMN supplementation, currently no adverse effects have 
been reported (Trammell et al. 2016a, Airhart et al. 2017).
Despite many studies reporting beneficial outcomes 
in disease models, and the absence of adverse effects from 
the clinical studies to date, there is still some concern 
about possible unwanted effects of elevating NAD+ 
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with particular focus surrounding immune responses. 
Numerous mechanistic studies have provided rationale 
for these concerns with an association found between 
raised NAD+ levels and pro-inflammatory effects (Van 
Gool  et  al. 2009, Preyat  et  al. 2016, Gerner  et  al. 2017). 
Notably, secretion of the pro-inflammatory cytokine 
TNF-α is responsive to intracellular NAD+ levels via a 
proposed SIRT6-based mechanism with loss of SIRT 
function able to reverse these effects (Van Gool et  al. 
2009). Although typically thought to be a pro-survival 
factor, NAD+ has also been found to regulate TNF-induced 
necroptosis, a regulated form of necrosis, via a SIRT-
dependent mechanism (Preyat et  al. 2016). SIRT1 has 
also been identified to induce pro-inflammatory effects 
by promoting T helper 17 effector cell generation and 
function (Lim et al. 2015). The use of NAMPT inhibitors to 
deplete cellular NAD+ levels has been explored in models 
of malignancy and inflammation with some studies 
showing promising effects (Montecucco  et  al. 2013b). 
For example, in disease models of colitis where NAMPT 
is upregulated in response to an increased turnover of 
NAD+ as a result of enhanced activity of NAD+-consuming 
enzymes, NAMPT inhibition was able to markedly supress 
key inflammatory processes (Gerner et al. 2017). Similar 
anti-inflammatory effects have been seen in models of 
arthritis, experimental autoimmune encephalomyelitis 
and myocardial ischaemia/reperfusion (Busso et al. 2008, 
Bruzzone et al. 2009, Montecucco et al. 2013a,b). Although 
to date there have been no reports of pro-inflammatory 
effects following vitamin B3 supplementation, these 
effects may become apparent following long-term 
precursor supplementation or in certain inflammatory 
disease states. As many of these pro-inflammatory 
mechanisms are thought to be mediated by SIRT activity 
perhaps the rise in nicotinamide, a known inhibitor of 
SIRT activity, consistently found following NR and NMN 
supplementation may provide a means of protection 
against deleterious effects (Bitterman et al. 2002).
Future research avenues
Understanding of the importance of NAD+ in metabolic 
health has greatly advanced in recent years and currently 
research is now focussed on further defining firstly the 
key pathways vital to maintaining NAD+ homeostasis 
but secondly establishing the most useful pathways to 
manipulate for enhanced NAD+ turnover. Many research 
challenges still remain including organism, tissue and 
organelle specificity as well circadian signalling and 
technical limitations for quantification. The identification 
of more robust biomarkers to monitor NAD+ turnover in 
health and disease would be extremely valuable.
In terms of clinical importance, many questions are 
still unanswered regarding the translational likelihood of 
NR and NMN salvage via the NRK enzymes. These include 
delivery of appropriate levels of substrate to target tissue, the 
best route of substrate delivery, dosing and timing taking 
into account circadian fluctuations in enzymes expression.
Furthermore, the function of NRK2 is still unclear, 
although it appears to play a redundant role in NAD+ 
biosynthesis along with NRK1, at least in unchallenged 
models, its highly regulated expression particularly in 
times of stress suggest it may have role beyond NAD+ 
metabolism.
Concluding remarks
The requirement of NRK1 and 2 to utilise exogenous 
NR and NMN has led to a new found interest into the 
regulation of this alternative NAD+ pathway. The notion 
of using NAD+ precursors to boost NAD+ is now beginning 
to see translation into human studies, appearing to be safe, 
naturally available, and having the potential to improve 
health outcomes across a large range of pathophysiological 
scenarios. NR and NMN supplementation are at the 
forefront of several clinical trials as a result of mounting 
evidence from a vast array of in vivo studies supporting 
their therapeutic potential. Despite this, there is still 
much more to learn about the NRK enzymes and how 
best to target NAD+ boosting therapies in order for them 
to maximise their effects. In terms of NAD+ biosynthesis, 
NRK1 appears to play a more crucial role upon exogenous 
delivery of NR. NRK2 is much more highly regulated 
with expression typically muscle specific except in 
times of injury of energetic stress where large changes 
to expression have been observed. Further work is now 
necessary to determine whether this induction is a purely 
adaptive response to acute loss of energy homeostasis or if 
there is a potential alternative function for NRK2 beyond 
NAD+ metabolism. The induction of NRK activity may 
also point to the tissues and scenarios in which NR and 
NMN may be most therapeutically effective.
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